GLP-1 Weight Loss: Why Percent Beats Pounds

You step on the scale, it says you're down 5%, and some quiet voice asks: is that it? Your feed is full of 40-pound drops and dramatic side-by-sides, and five percent starts to feel like a rounding error next to all of it.

It isn't. Here's the part the scale leaves out: in obesity medicine, 5% is roughly where the interesting stuff begins.

The scale is measuring the wrong thing

Weight on its own is a lousy yardstick. Ten pounds (about 4.5 kg) means one thing for someone starting at 150 pounds and something else entirely for someone starting at 250. For the first person, that's nearly 7% of their body weight. For the second, it's about 4%. Same ten pounds, different bodies, different meaning.

So clinicians don't grade weight loss in pounds or kilograms. They grade it in percent of body weight. And the number they watch for isn't dramatic. Obesity guidelines in the US and UK point to a modest loss, somewhere in the 5% to 10% range, as enough to produce clinically meaningful improvements in health. Not a cosmetic change. A measurable, shows-up-on-your-labs change.

Success gets measured in percent, not pounds, for a simple reason: percent tells you how much of you is different. Pounds can't.

What actually happens at 5%

So what does that first 5% actually buy you?

In one tightly controlled weight-loss study, people who dropped 5% of their body weight improved insulin sensitivity in the three tissues that matter most for blood sugar: fat, liver, and muscle. Their beta cells — the pancreatic cells that release insulin — started working better too. In plain terms, the machinery your body uses to manage blood sugar began running cleaner.

One thing to be clear about, because it changes how you read the result. That study was diet-induced weight loss. Not a GLP-1 trial. The people in it lost the weight the old-fashioned way, under supervision. So the takeaway isn't "the drug fixed insulin sensitivity at 5%." It's that losing the weight—however you get there—is what moved those markers. A GLP-1 is one way to reach that 5%. The benefit belongs to the weight loss, not to any particular route to it.

It was also a small study: group averages from a handful of participants, 19 in the 5% group. Enough to see a real signal, not enough to promise you personally the same numbers. Bodies vary. Read it as "this is the kind of thing that improves," not "this will happen to me by Tuesday."

Does losing more do more? The 5, 11, 16 staircase

The same study was built to answer the obvious follow-up: if 5% helps, does more help more?

The researchers deliberately compared graded amounts of weight loss—groups who lost about 5%, about 11%, and about 16%—so they could watch what each additional slice adds. Body composition and several cardiometabolic risk factors improved at 5%, and losing more produced further benefits on top of that.

Take that table gently. The trend is real, but it's a group-level pattern, not a per-percent rule you can bank on. Nobody gets a fixed unit of health for each unit of weight. And notice how the groups shrink to nine people at the higher tiers. These are direction-of-travel findings, not a dosing chart for your own metabolism. "More tends to help more, on average" is about as far as the numbers will stretch.

But 5% isn't a cliff

Here's the flip side, and it matters if you've lost 3% or 4% and feel like you're flunking the test.

Five percent isn't a magic gate that switches health benefits on. A 2024 systematic review looked at lower-level weight loss and found measurable improvements even below 5%, and it warned against fixating on hitting one exact threshold. The benefit is continuous. It doesn't wait politely at the 5% line and then flip a switch.

So 5% to 10% is a useful marker, not a border wall. If you're under it and pointed the right way, that direction already counts for something.

The threshold is shorthand: a round number that lets guidelines and studies agree on what "meaningful" means. Your body never read the guideline.

Where GLP-1 medicines land

Now put GLP-1 medicines on that same percent scale, and the picture reframes itself.

These drugs routinely clear the 5% to 10% range and keep going. In STEP 1, once-weekly semaglutide at 2.4 mg—the obesity dose sold as Wegovy, the same molecule as Ozempic at lower diabetes doses—produced a mean weight change of −14.9% at week 68, against −2.4% on placebo. In SURMOUNT-1, tirzepatide at its 15 mg dose—Zepbound for obesity, Mounjaro for diabetes—produced a mean change of −20.9% at week 72, against −3.1% on placebo, landing near a fifth of body weight.

Resist the urge to stack those two numbers and crown a winner. They come from different trials, different drugs, different doses, and different timepoints. That's not a direct comparison, and reading it as one is a mistake the data doesn't support. What both trials do show is scale: averages well past the 5% to 10% threshold, up in the 15% to 20% neighborhood.

And "average" is the load-bearing word. The −14.9% and −20.9% figures are trial means. Some people land above them, some well below, because response varies a lot from one person to the next. If you're sitting at 5% or 8%, you aren't behind some curve. You're inside the range where health markers already move.

So should you aim for as much as possible?

It's tempting to read all of this as "lose as much as you can." That's the wrong lesson.

Go back to the first fact: 5% to 10% is already where meaningful improvement shows up. The goal was never the smallest possible number on the scale. It's health, physical function, and something you can hold onto. Chasing the maximum isn't necessary for everyone, and it isn't automatically safer either—rapid or extreme loss carries its own trade-offs, from muscle loss to gallstones to falling short on nutrition.

A 5% to 10% loss you can keep beats a dramatic drop that costs you muscle and bounces back. The number that helps is the one you can live with.

What's realistic for your body, your starting point, and your history is a conversation between you and your clinician—not a contest against whatever's scrolling past on your phone. Those posts are a highlight reel, not a controlled trial, and certainly not your physiology.

Who it's not for — and when to check in

None of this means the medicines suit everyone, and the safety picture comes in clear tiers. Keeping them straight matters, because they are not the same level of concern.

At the top sits an absolute contraindication. If you have a personal or family history of medullary thyroid carcinoma, or the genetic syndrome MEN2 (multiple endocrine neoplasia type 2), semaglutide (Wegovy)—and tirzepatide (Zepbound) alike—is off the table. In the US, that's a boxed warning, the strongest flag the FDA uses, and it's a class warning: both drugs' labels carry it, so it holds whichever of these GLP-1 medicines you're on.

One step down is a warning and precaution: acute pancreatitis. It isn't an absolute bar, but the US label says to stop the medicine and get evaluated if pancreatitis is suspected.

Then there's the everyday tier, the common stuff most people actually run into. Nausea, vomiting, diarrhea, and constipation are the usual companions, especially in the early weeks as the dose steps up. Uncomfortable, usually manageable, and not in the same category as the two above.

One caveat on all of that: the boxed warning and the label wording are the US FDA's. Approvals, indications, and exact language differ elsewhere—the MHRA in the UK, the EMA in Europe, and other regulators each write their own—so a US brand or its US label isn't a global rulebook.

Which brings it back to where we started. You're down 5% and wondering whether it counts? It counts. The scale was just answering the wrong question. Everything above comes from published trials and peer-reviewed research, not from anyone who has met you—so what to aim for, which medicine fits, and whether to change or stop a dose are all worth settling with the doctor who has.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app